Sarcoma 37

Download PDF

Recent Publications on Sarcoma 37:
[Antineoplastic properties of extracellular fructoso-1,6-bisphosphatase of Bacillus subtilis 668 and preparation isolated from cultural liquids of Bacillus subtilis 7025] It was shown for the first time that extracellular FBPase of B. subtilis...	22nd September, 2007		Mikrobiol Z. 2007 May-Jun;69(3):68-73.
[Influence of probiotic subalin on efficiency of antitumor vaccine] Preparation subalin created on the basis of a recombinant strain of B....	13th February, 2007		Mikrobiol Z. 2006 Nov-Dec;68(6):51-8.
Antitumor resistance activation in mice: can the immunological memory cells enhance resistance? Immunization of adult animals with the Ehrlich ascytic cancer cells...	2nd June, 2006	R.E. Kavetsky Institute of Experimental Pathology, Oncology and	J Exp Clin Cancer Res. 2005 Dec;24(4):585-93.
Elevation of the efficacy of antitumor vaccine prepared on the base of lectines from B. subtilis B-7025 upon its combined application with probiotics in vivo. The aim of the work was to evaluate in vivo the possible enhancement of...	3rd March, 2006	R.E. Kavetsky Institute of Experimental Pathology, Oncology and	Exp Oncol. 2005 Dec;27(4):336-8.
Response of the thymus and spleen of CBA mice with sarcoma 37 on intravenous and subcutaneous administration of syngeneic dendritic cells. OBJECTIVE: To compare the effect of intravenous (i/v) and subcutaneous...	16th December, 2005	Department of Clinical Immunology, Institute of Oncology AMSc of Ukraine,	Exp Oncol. 2005 Sep;27(3):206-9.
→View more research publications.

BioNews Results for Sarcoma 37:
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors	The Business Journal Phoenix:  Aug 27 2008 11:51AM Matching: sarcoma 37
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors	Atlanta Business Chronicle:  Aug 27 2008 11:49AM Matching: sarcoma 37
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors	San Antonio Business Journal:  Aug 27 2008 11:38AM Matching: sarcoma 37
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors	Portland Business Journal:  Aug 27 2008 11:34AM Matching: sarcoma 37
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors	Nashville Business Journal:  Aug 27 2008 11:33AM Matching: sarcoma 37
Promote your company here: BioNewsCast - Press Release Distribution	→View more news.

Sarcoma 37 Patents:
US Patent No.	Title
7410656	Anti-cancer compounds
6080741	Arglabin compounds and therapeutic uses thereof
6020365	Arglabin compounds and therapeutic uses thereof
5902809	Arglabin compounds and therapeutic uses thereof
5858988	Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Sarcoma 37 scientists - we have details of around 37 individuals working on Sarcoma 37 .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.